Introduction of SARS‐COV‐2 C.37 (WHO VOI lambda) from Peru to Italy

We report here the introduction of SARS-COV-2 C.37, a variant of interest (VOI) recently renamed “lambda” by WHO, from Peru to Italy. We discuss mutations of concern in this lineage, and evidences for impaired sensitivity to neutralizing antibody-therapeutics and vaccines.

Saved in:
Bibliographic Details
Published inJournal of Medical Virology Vol. 93; no. 12; pp. 6460 - 6461
Main Authors Baj, Andreina, Novazzi, Federica, Ferrante, Francesca D., Genoni, Angelo, Cassani, Gianluca, Prestia, Martina, Colombo, Alberto, Capuano, Riccardo, Zago, Christian, Pasciuta, Renee, Tamborini, Antonio, Rossi, Agostino, Tettamanzi, Elena, Catanoso, Giuseppe, Focosi, Daniele, Maffioli, Lorenzo, Maggi, Fabrizio
Format Journal Article Web Resource
LanguageEnglish
Published Hoboken John Wiley & Sons, Inc 01.12.2021
Wiley Subscription Services, Inc
John Wiley and Sons Inc
Subjects
Letter to the Editor
Severe acute respiratory syndrome coronavirus 2
Virology
Online AccessGet full text

Cover

More Information
Summary:We report here the introduction of SARS-COV-2 C.37, a variant of interest (VOI) recently renamed “lambda” by WHO, from Peru to Italy. We discuss mutations of concern in this lineage, and evidences for impaired sensitivity to neutralizing antibody-therapeutics and vaccines.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.27235